Medacta Reports on Device Utilization

By Julie A. Vetalice

Results from a 421-patient study revealed a 97.75% survival rate at 5 years for Medacta's AMIStem hip implant, suggesting that the device is a safe and reliable solution for cementless total hip arthroplasty (THA).

AMIStem system is often used with Medacta’s Anterior Minimally Invasive Surgery (AMIS) approach to THA. To date, AMIStem has been used >100,000 times, and the AMIS technique performed >200,000 times.

Medacta's CT-based MyKnee instrumentation comprises patient-matched cutting blocks. Results from a study of 222 consecutive total knee arthroplasties revealed that patients from the MyKnee group displayed a signficant improvement in function and pain scores vs. those in the conventional instrument group, with greater alignment accuracy. To day, >40,000 MyKnee procedures have been performed.

Other study results on Medacta's GMK Sphere total knee and MySpine patient-matched pedicle screw were also highlighted.

Sources: Medacta International; ORTHOWORLD

Product Labels: Hip Replacement

Tags: Trial/Study